GSK shares higher after Delaware Zantac ruling
GSK PLC (LSE:GSK, NYSE:GSK) shares opened higher after Delaware's Supreme Court said it will hear an appeal by the UK drug market and other pharmaceutical companies, including Pfizer, Sanofi, and Boehringer Ingelheim, to dismiss over 70,000 lawsuits alleging that the discontinued heartburn drug Zantac causes cancer. The companies argue that the scientific methods used by plaintiffs to link Zantac to cancer are unsound.
GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag
The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.
GSK gets fast-track approval from FDA for Chinese lung cancer drug
GSK PLC (LSE:GSK, NYSE:GSK) has received the green light for a speedier US regulatory process for a potential new cancer drug being developed with a Chinese partner. The pharmaceuticals developer said it has received 'breakthrough therapy designation' from the US Food and Drug Administration (FDA) for the antibody-drug conjugate to treat relapsed or refractory extensive-stage small-cell lung cancer, an aggressive form of lung cancer.
GSK's discount unwarranted, especially with latest Zantac win, says broker
British pharma multinational GSK PLC (LSE:GSK, NYSE:GSK) has persistently been undervalued against its international peer set due to merited fears over the high-profile Zantac litigation. But with recent victories in the US courts, is this discount beginning to look unfair?
GSK to seek dismissal of Florida case against heartburn drug Zantac
British drugmaker GSK said on Friday it would seek a dismissal of an upcoming Zantac case in Florida, where plaintiffs alleged that its discontinued heart burn drug had caused prostate cancer.
GSK wins favourable ruling in US Zantac litigation
GSK PLC (LSE:GSK, NYSE:GSK) has secured a legal victory in the ongoing Zantac (ranitidine) litigation, with the Florida State court in the US excluding the plaintiffs' expert testimony as unreliable. Thousands of lawsuits have been filed against the British drugmaker alleging that the Zantac heartburn medication's active ingredient ranitidine causes cancer.
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platform Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areas Invoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreement Dosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMO Strengthening of Supervisory Board with appointment of innovation expert Birgit Hoffman and clinical oncologist Mehdi Shahidi, M.D. Chief Financial Officer, Pierre Kemula, to step down at the end of his term October 31, 2024; search for a replacement ongoing with transition plan in place Cash and cash equivalents position of €202.5 million as of June 30, 2024, not including €400 million upfront payment from GSK agreement; reaffirming cash runway into 2028 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V.
GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
German panel endorses GSK, Pfizer RSV vaccines for elderly
Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV.
GSK wins Illinois court battle
GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury found that the product was not responsible for plaintiff Carrie Joiner's colorectal cancer. Joiner had alleged that she developed cancer from a carcinogenic contaminant called NDMA in the blockbuster pill.
GSK wins latest trial over Zantac cancer claims
GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spokesperson said.
India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand
India's GlaxoSmithKline Pharmaceuticals reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines.
